Latest Filings

Issuer Activity

Overview :: Genomic Health, Inc. (OQ:GHDX) [?]
Business Focus: Biotechnology & Medical Research Share on StockTwits
Recent Price for GHDX
USD 27.650 -0.310 (-1.109%)
NSQ Delayed 15 minutes
10:22 EDT
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
27.910 37.240 N/A 6,374 871.73
1-Day Low 52-Week Low Yield Avg. Volume  
27.570 23.900 0.0% NSQ  
Log in or sign up for a free account to add this stock to your watch list. During beta also get free PDF company reports for US stocks.

Latest 10 SEC filings (by transaction date) for GHDX within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 10:37am ET August 20th, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Aug 15/14 Aug 14/14 Shak Steven Direct Ownership Employee Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -6,348  
Aug 15/14 Aug 14/14 Shak Steven Direct Ownership Common Stock S - Open market or private sale -6,348 $27.49
Aug 15/14 Aug 14/14 Shak Steven Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 6,348 $2.88
Aug 15/14 Aug 13/14 Shak Steven Direct Ownership Employee Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -7,000  
Aug 15/14 Aug 13/14 Shak Steven Direct Ownership Common Stock S - Open market or private sale -7,000 $27.25
Aug 15/14 Aug 13/14 Shak Steven Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 7,000 $2.88
Aug 14/14 Aug 12/14 Popovits Kimberly J Direct Ownership Employee Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -3,000  
Aug 14/14 Aug 12/14 Popovits Kimberly J Direct Ownership Common Stock S - Open market or private sale -3,000 $26.07
Aug 14/14 Aug 12/14 Popovits Kimberly J Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 3,000 $9.39
Jul 16/14 Jul 14/14 Popovits Kimberly J Direct Ownership Employee Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -3,000  
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Latest 10 SEC filings (by filing date) for GHDX within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 10:37am ET August 20th, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Aug 15/14 Aug 14/14 Shak Steven Direct Ownership Employee Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -6,348  
Aug 15/14 Aug 13/14 Shak Steven Direct Ownership Employee Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -7,000  
Aug 15/14 Aug 14/14 Shak Steven Direct Ownership Common Stock S - Open market or private sale -6,348 $27.49
Aug 15/14 Aug 14/14 Shak Steven Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 6,348 $2.88
Aug 15/14 Aug 13/14 Shak Steven Direct Ownership Common Stock S - Open market or private sale -7,000 $27.25
Aug 15/14 Aug 13/14 Shak Steven Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 7,000 $2.88
Aug 14/14 Aug 12/14 Popovits Kimberly J Direct Ownership Employee Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -3,000  
Aug 14/14 Aug 12/14 Popovits Kimberly J Direct Ownership Common Stock S - Open market or private sale -3,000 $26.07
Aug 14/14 Aug 12/14 Popovits Kimberly J Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 3,000 $9.39
Jul 16/14 Jul 14/14 Popovits Kimberly J Direct Ownership Employee Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -3,000  
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Sign up for a free account or login above to see the past 6 months of filings sorted by insider. During our beta offer, get free access to company PDF reports.
Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Key People
Kimberly J. Popovits
Chairman of the Board, President, Chief Executive Officer
G. Bradley Cole
Chief Financial Officer, Chief Operating Officer, Principal Financial Officer, Principal Accounting Officer
Steven Shak
Executive Vice President - Research and Development
Company Contact
Address: 301 Penobscot Drive
REDWOOD CITY CA 94063
Tel: N/A
Website: www.genomichealth.com
IR: investor.genomichealth.com
Business Overview
Genomic Health, Inc. (Genomic Health) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR), in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. As of February 2012, Oncotype DX was evaluated in invasive breast cancer in 13 clinical studies involving more than 4,000 breast cancer patients worldwide. Genomic Health offers its Oncotype DX tests as a clinical service. In March 2012, the Company established a wholly owned subsidiary, InVitae Corporation.
Financial Overview
For the six months ended 30 June 2014, Genomic Health, Inc. revenues increased 8% to $137.5M. Net loss increased from $3.9M to $12.1M. Revenues reflect Other Foreign segment increase of 32% to $23.4M, United States segment increase of 5% to $114.1M. Higher net loss reflects Personnel-related expenses increase of 22% to $33.6M (expense), Other Selling and marketing increase of 28% to $21M (expense).
Employees: 684 as of Dec 31, 2013
Reporting Currency: U.S. Dollars
Enterprise value: $775.80M as of Jun 30, 2014
Annual revenue (TTM): $272.29M as of Jun 30, 2014
EBITDA (TTM): -$13.17M as of Jun 30, 2014
Net annual income (TTM): -$20.94M as of Jun 30, 2014
Free cash flow (TTM): -$4.28M as of Jun 30, 2014
Net Debt Last Fiscal Year: N/A
Shares outstanding: 31,527,345 as of Jul 31, 2014
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
Quintiles Transnational H (N:Q)
United Therapeutics (OQ:UTHR)
Seattle Genetics (OQ:SGEN)